Development and Validation of Epigenetic Signature Predict Survival for Patients with Laryngeal Squamous Cell Carcinoma

Establishing epigenetic signature to improve the accuracy of survival prediction and optimize therapeutic strategies for laryngeal squamous cell carcinoma (LSCC) by a genome-wide integrated analysis methylation transcriptome. LSCC DNA datasets RNA sequencing were acquired from Cancer Genome Atlas (TCGA). MethylMix was applied detect methylation-driven genes (MDGs), which developed an signature. The predictive clinical value evaluated receiver operating characteristic decision curve analysis, compared with tumor-node-metastasis (TNM) stage system. In addition, prognostic validated external Gene Expression Omnibus (GEO) database. According five MDGs signature, candidate small molecules screen out CMap A total 88 identified, (MAGEB2, SUSD1, ZNF382, ZNF418, ZNF732) chosen construct can effectively divide patients into high-risk low-risk group, area under (AUC) 0.8 (5-year overall [OS]) AUC 0.745 (3-year OS). Stratification affirmed that still significant statistical model in subsets different variables. Multivariate Cox regression indicated efficacy appears independent other clinicopathological characteristics. terms capacity usefulness, superior traditional TNM stage. confirmed cohorts GEO. Finally, matched 10 most as promising drugs reverse gene expression. An MDGs, identified integrating multidimensional genomic data, may offer novel research directions prospects individualized treatment LSCC.